Nuvectis Begin Period Cash Flow from 2010 to 2024
| NVCT Stock | USD 5.04 0.24 4.55% |
Begin Period Cash Flow | First Reported 2010-12-31 | Previous Quarter 20 M | Current Value 12.1 M | Quarterly Volatility 3.5 M |
Check Nuvectis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvectis Pharma's main balance sheet or income statement drivers, such as Interest Expense of 179.9 K, Selling General Administrative of 4.6 M or Selling And Marketing Expenses of 13.2 K, as well as many indicators such as Price To Sales Ratio of 510, Dividend Yield of 0.0 or PTB Ratio of 11.17. Nuvectis financial statements analysis is a perfect complement when working with Nuvectis Pharma Valuation or Volatility modules.
Nuvectis | Begin Period Cash Flow |
Latest Nuvectis Pharma's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Nuvectis Pharma over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Nuvectis Pharma's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvectis Pharma's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Nuvectis Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 8,292,287 | |
| Geometric Mean | 7,870,661 | |
| Coefficient Of Variation | 42.23 | |
| Mean Deviation | 2,065,297 | |
| Median | 7,214,000 | |
| Standard Deviation | 3,502,241 | |
| Sample Variance | 12.3T | |
| Range | 14.3M | |
| R-Value | 0.47 | |
| Mean Square Error | 10.3T | |
| R-Squared | 0.22 | |
| Significance | 0.08 | |
| Slope | 369,232 | |
| Total Sum of Squares | 171.7T |
Nuvectis Begin Period Cash Flow History
About Nuvectis Pharma Financial Statements
Nuvectis Pharma shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Nuvectis Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in Nuvectis Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nuvectis Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 20 M | 12.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.